Modality
Degrader
MOA
Anti-Tau
Target
JAK1
Pathway
Autophagy
Angelman
Development Pipeline
Preclinical
~Aug 2023
→ ~Nov 2024
Phase 1
Feb 2025
→ Mar 2027
Phase 1Current
NCT03176609
1,429 pts·Angelman
2025-02→2027-03·Recruiting
1,429 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-1111mo awayPh2 Data· Angelman
Trial Timeline
Q2Q3Q42026Q2Q3Q42027
P1/2
Recruit…
Catalysts
Ph2 Data
2027-03-11 · 11mo away
Angelman
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03176609 | Phase 1/2 | Angelman | Recruiting | 1429 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |